Divi's Laboratories Limited vs Parmax Pharma Ltd
A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Parmax Pharma Ltd (PARMAX) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Divi's Laboratories Limited leads DIVISLAB vs PARMAX on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability31
- Growth10
- Size & financial health30
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
DIVISLAB takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
DIVISLAB takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
- − ["Stock is trading at 14.39 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
- + []
- − ["The company has delivered a poor sales growth of -14.3% over past five years.", "Company reported a net loss of ₹4 Cr in its latest financial year."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.